Annenberg Oncology

On-line Courses

  • CME:
    Advanced Basal Cell Carcinoma: How to Navigate Challenging Clinical Scenarios with Systemic Treatment
    CME Credit: 2.00 AMA
  • CME:
    Immunotherapy Advances in RRMM: An Educational Journey
    CME Credit: 1.00 AANP AMA ANCC CABRN

Events

News and Perspectives

COVID-19: ASCO Patient Care Link

American Society of Clinical Oncology (ASCO) Patient Care Recommendations

Read more...
Added 11 months ago Web Resource

COVID-19: ASH Resources

American Society of Hematology (ASH) Resources

Read more...
Added 11 months ago Web Resource

COVID-19: NCCN Recommendations

National Comprehensive Cancer Network (NCCN) Recommendations

Read more...
Added 11 months ago Web Resource

COVID-19: ASCO Provider and Practice Link

American Society of Clinical Oncology (ASCO) Provider and Practice Recommendations

Read more...
Added 11 months ago Web Resource

Prostate Cancer: More positive data from TITAN trial

A double-blind, phase 3 TITAN trial, which randomly assigned patients with metastatic castration-sensitive prostate cancer to receive apalutamide or placebo, in addition to continuous androgen deprivation therapy (ADT), previously demonstrated significant improvement in radiographic progression-free survival (PFS) and overall survival in patients who received apalutamide (Chi KN, et al. N Engl J Med. 2019;381:13-24). At the 2020 Genitourinary Cancers Symposium, post hoc analysis data were presented which showed that addition of apalutamide to ADT also prolonged PFS2 (defined as the time from randomization to disease progression on 1st subsequent prostate cancer therapy or death, whichever occurred first) regardless of the type (hormonal or taxane) of the 1st subsequent life-prolonging therapy.

Read more...
Added 11 months ago Abstract

Multiple Myeloma: Positive ICARIA-MM Data Lead to Isatuximab FDA Approval

On March 2, 2020, FDA approved an anti-CD38 monoclonal antibody isatuximab in combination with pomalidomide and low-dose dexamethasone (Isa-Pd) for patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. This approval was based on the positive progression-free survival (PFS) data from a randomized, open-label, two-arm, phase 3 trial, ICARIA-MM; at a median follow-up of 11.6 months, median PFS was 11.5 months in the Isa-Pd arm versus 6.5 months in the Pd arm. Isatuximab represents an important new treatment option for patients with RRMM, especially those who are refractory to lenalidomide and a proteasome inhibitor.

Read more...
Added 11 months ago Article

Myeloma: Update from Orlando

Dr. Joseph Mikhael of the Translational Genomics Research Institute in Phoenix, Arizona, shares his perspective on new multiple myeloma data.

Added 1 year ago Video

Myeloma: Update from Orlando

Dr. Ola Landgren of Memorial Sloan Kettering Cancer Center in New York City, shares his perspective on new multiple myeloma data."

Added 1 year ago Video

PNCA: The Impact of Translational Science on Cancer

Dr. Linda Malkas of City of Hope presents the Grand Rounds lecture at Eisenhower Health where she talks about her journey toward identifying proliferating cell nuclear antigen (PCNA) as a potentially major player in cancer, and an early development of a small molecule inhibitor of a cancer-associated form of PCNA. She also discusses potential advantages of targeting molecular hubs, as opposed to targeting enzymatic activities, of cancer cells.

Added 1 year ago Video

Myeloma: Update from Orlando

Dr. Shaji Kumar of Mayo Clinic in Rochester, Minnesota, shares his perspective on new multiple myeloma data.

Added 1 year ago Audio

Prostate Cancer: Update from Chicago

Neal D. Shore, MD, reviews exciting new prostate cancer data.

Added 1 year ago Video

Bladder Cancer: Update from Chicago

Guru P. Sonpavde, MD, shares exciting new bladder cancer data.

Added 1 year ago Video

Lymphocytic Leukemia: Update from Chicago

Kanti R. Rai, MD, shares exciting new chronic lymphocytic leukemia data.

Added 1 year ago Video

Multiple Myeloma: Update from Chicago

Joseph Mikhael, MD, gives his perspective on new daratumumab data.

Added 1 year ago Video

Advance or Metastatic Urothelial Cancer: Update from Chicago

Daniel P. Petrylak, MD, gives an update on enfortumab vedotin EV-201 trial

Added 1 year ago Video